DiaMedica Therapeutics Q3 loss widens on higher R&D costs

By Reuters News


Overview

  • US biopharma firm's Q3 net loss widened yr/yr and missed analyst estimates

  • Q3 loss per share met analyst expectations


Outlook

  • Company expects ReMEDy2 interim analysis in acute ischemic stroke trial to complete in Q1 2027

  • DiaMedica anticipates current cash will fund operations into Q4 2027

  • Company expects R&D expenses to moderately increase as clinical trials progress


Result Drivers

  • R&D EXPENSES - Higher R&D costs driven by expansion of clinical team, ongoing ReMEDy2 trial, start-up of Phase 2 preeclampsia trial, additional toxicity testing, and increased manufacturing activity

  • G&A EXPENSES - Slight decrease in G&A expenses attributed to lower professional fees, partially offset by higher share-based compensation


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

Meet

$0.21

$0.21 (4 Analysts)

Q3 Net Loss

Miss

$11.31 mln

$10.96 mln (3 Analysts)

Q3 Cash & Investments

$34.9 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for DiaMedica Therapeutics Inc is $14.00, about 44.9% above its November 11 closing price of $9.66


Reuters Recommended Reads

  • Nov 12 - Assembly Biosciences Q3 net loss widens on increased R&D costs

  • Nov 12 - Nektar Therapeutics Q3 loss widens on higher R&D and G&A expenses

  • Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk